Shots:

• The P-II study involves assessing of BI 425809 (4 oral doses- qd) vs PBO over 12wks. treatment period in schizophrenia patients. The results are presented at the 33rd ECNP Congress
• Results: met its 1EPs and showed improvement in cognition in stable adult schizophrenia patients. The results are being further evaluated in cognitive impairment associated with schizophrenia
• BI 425809 is an orally administered- glycine transporter-1 inhibitor and a key component of Boehringer Ingelheim’s CNS research program. The results along with an ongoing combination P-II study of BI 425809 and adjunctive computerized cognitive training- will help determine the direction for BI 425809 in further schizophrenia research

­ Ref: Buisness wire | Image: GMP News